Home
Forums
New Posts
Illini Basketball
Illini Football
Sports Talk
Log in
Register
What's new
Menu
Log in
Register
Install the app
Install
Forums
General
Chat
Trading Stock/Investing
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="DaytonIllini" data-source="post: 1041517"><p>Also keep an eye on Astellas Pharma. </p><p></p><p>It's a Japanese company that trades on the Tokyo exchange. There are a couple ADR's and I don't know the difference between them (I bought on the Tokyo exchange). They have two big oncology drugs Tarceva and Xtandi. The first is selling pretty well in non-small cell cancer of the lung and the other appears to be gaining ground in the metastatic castrate resistant prostate cancer market. It's a pill and has a more benign side effect profile than the chemotherapy alternative. It does go up against Xytiga (abiraterone) and ongoing phase 3 trials are being done to see if Xtandi vs. Zytiga is better. Zytiga has to be given with prednisone though and that can be a problem for older men who may be type 2 diabetics. Using the KISS principle I think Xtandi might be the better first line drug reserving Zytiga for Xtandi failures. </p><p></p><p>There is also another study looking at the two drugs together vs. one or the other by itself. Since both work on separate parts of the androgen receptor (AR) axis there may be an additive effect. Xtandi is a highly active AR antagonist. Zytiga works on the Cyp17 pathway as an inhibitor of androgen synthesis.</p></blockquote><p></p>
[QUOTE="DaytonIllini, post: 1041517"] Also keep an eye on Astellas Pharma. It's a Japanese company that trades on the Tokyo exchange. There are a couple ADR's and I don't know the difference between them (I bought on the Tokyo exchange). They have two big oncology drugs Tarceva and Xtandi. The first is selling pretty well in non-small cell cancer of the lung and the other appears to be gaining ground in the metastatic castrate resistant prostate cancer market. It's a pill and has a more benign side effect profile than the chemotherapy alternative. It does go up against Xytiga (abiraterone) and ongoing phase 3 trials are being done to see if Xtandi vs. Zytiga is better. Zytiga has to be given with prednisone though and that can be a problem for older men who may be type 2 diabetics. Using the KISS principle I think Xtandi might be the better first line drug reserving Zytiga for Xtandi failures. There is also another study looking at the two drugs together vs. one or the other by itself. Since both work on separate parts of the androgen receptor (AR) axis there may be an additive effect. Xtandi is a highly active AR antagonist. Zytiga works on the Cyp17 pathway as an inhibitor of androgen synthesis. [/QUOTE]
Verification
Post reply
Forums
General
Chat
Trading Stock/Investing
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…